



# Substance Use

Guidelines for the identification and  
management of substance use  
and substance use disorders  
in pregnancy



Guidelines for the identification and  
management of substance use  
and substance use disorders  
in pregnancy

## **WHO Library Cataloguing-in-Publication Data**

Guidelines for the identification and management of substance use and substance use disorders in pregnancy.

1.Substance-Related Disorders – prevention and control 2.Psychotropic Drugs – adverse effects. 3.Pregnancy. 4.Pregnancy Outcome. 5.Prenatal Exposure Delayed Effects. 6.Guideline. I.World Health Organization.

ISBN 978 92 4 154873 1

(NLM classification: WQ 210)

### **© World Health Organization 2014**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

# CONTENTS

<b>Acknowledgements</b> .....	iii
<b>Glossary of terms used in these guidelines</b> .....	v
<b>Acronyms &amp; abbreviations</b> .....	viii
<b>Executive summary</b> .....	x
<b>Introduction</b> .....	1
<b>Why these guidelines were developed</b> .....	1
<b>Existing relevant guidelines on related problems and disorders</b> .....	2
<b>Who should use these guidelines</b> .....	3
<b>Objectives and scope of the document</b> .....	3
<b>Individuals and partners involved in development of the guidelines</b> .....	3
<b>How the guidelines were developed</b> .....	4
<b>Evidence search and retrieval</b> .....	4
<b>Evidence to recommendations</b> .....	6
<b>Recommendations</b> .....	6
Overarching principles .....	6
Screening and brief interventions for hazardous and harmful substance use during pregnancy .....	8
Psychosocial interventions for substance use disorders in pregnancy .....	9
Detoxification or quitting programmes for alcohol and other substance dependence in pregnancy .....	10
Pharmacological treatment (maintenance and relapse prevention) for alcohol and other substance dependence in pregnancy .....	13
Breastfeeding and maternal substance use .....	15
Management of infants exposed to alcohol and other psychoactive substances .....	17
<b>Research priorities and gaps</b> .....	19
<b>Plans for disseminating, adapting and implementing these recommendations</b> .....	21
<b>Evaluating the impact of these recommendations</b> .....	21
<b>Review by date</b> .....	21
<b>Annex 1: Evidence Profiles</b> .....	22
<b>Evidence Profile 1: Screening and brief interventions</b> .....	22
Evidence question .....	22
Selection criteria for the systematic review .....	22
Evidence to recommendations table .....	23
Summary of findings and GRADE tables .....	28

<b>Evidence Profile 2: Psychosocial interventions for harmful use and dependence on alcohol and other substances in pregnancy</b> . . . . .	44
Evidence question . . . . .	44
Selection criteria for the systematic review . . . . .	44
Evidence to recommendations table . . . . .	45
Summary of findings and GRADE tables . . . . .	50
<b>Evidence Profile 3: Detoxification or quitting programmes for alcohol and other substance dependence in pregnancy</b> . . . . .	93
Evidence question . . . . .	93
Selection criteria for the systematic review . . . . .	93
Evidence to recommendations table . . . . .	94
<b>Evidence Profile 4: Pharmacological treatment (maintenance and relapse prevention) for alcohol and other substance dependence in pregnancy</b> . . . . .	100
Evidence question . . . . .	100
Selection criteria for the systematic review . . . . .	100
Evidence to recommendations table . . . . .	100
Summary of findings and GRADE tables . . . . .	104
<b>Evidence Profile 5: Breastfeeding</b> . . . . .	122
Evidence question . . . . .	122
Selection criteria for the systematic review . . . . .	122
Evidence to recommendations table . . . . .	123
<b>Evidence Profile 6: Management of infants exposed to alcohol and other psychoactive substances</b> .	135
Evidence question . . . . .	135
Study selection criteria for the systematic review . . . . .	135
Evidence to recommendations table . . . . .	136
Summary of findings and GRADE tables . . . . .	142
<b>Annex 2: Systematic review methodology</b> . . . . .	182
Methods . . . . .	182
Criteria for considering studies for this review . . . . .	182
Data collection and analysis . . . . .	183
Main results . . . . .	188
<b>Annex 3: Screening instruments for substance use in prenatal or pregnant women</b> . . . . .	198
<b>Annex 4: Composition of guideline groups</b> . . . . .	200
WHO Steering Group . . . . .	200
Guideline Development Group (GDG) . . . . .	201
External reviewers . . . . .	202
<b>Annex 5: Declarations of interest</b> . . . . .	203
GDG members . . . . .	203
Consultants supporting GDG . . . . .	203
External reviewers . . . . .	204

# ACKNOWLEDGEMENTS

These guidelines were produced by the WHO Department of Mental Health and Substance Abuse (Management of Substance Abuse unit), in collaboration with the WHO Prevention of Noncommunicable Diseases Department (PND) and the United Nations Office on Drugs and Crime (UNODC) Prevention, Treatment and Rehabilitation Section (PTRS). The development of these guidelines was coordinated by Vladimir Poznyak and Nicolas Clark under the direction of Shekhar Saxena and in collaboration with Edouard Tursan d'Espaignet and Lubna Bhatti (WHO) and Elizabeth Mattfeld (UNODC).

The project had a **WHO Steering Group** with the following members: Avni Amin, Lubna Bhatti, Nicolas Clark, Ahmet Metin Gulmezoglu, Mathews Mathai, Mario Meriardi, Vladimir Poznyak, Shekhar Saxena, Edouard Tursan d'Espaignet (see annex for affiliations).

The members of the project's **Guideline Development Group** were: Sawitri Assanangkornchai, Guilherme Borges (Co-chair), Grace Chang, Anju Dhawan Dutta, Elizabeth Elliott, Katherine Everett-Murphy, Gabriele Fischer, Erikson Furtado, Hendree Jones, Fareed A. Minhas, Alice Ordean, Gabrielle Katrine Welle-Strand (Co-chair) (see annex for affiliations).

The **external peer reviewers** were: Steve Allsop, Espen Ajo Arnevik, Matthew Chersich, Andreea Creangea, Marica Ferri, David A. Fiellin, Louise Floyd, Chris Howson, Irma Kirtadze, Yukiko Kusano, Andre B. Lalonde, Carla Marienfeld-Calderon, Nester Moyo, Michael Farrell, Dzianis Padruchny, Roland Simon, Anna Woods (see annex for affiliations).

## **WHO would like to acknowledge the contributions made by the following individuals to the development of these guidelines:**

*Consultants:* Elizabeth Byrnes, Andrea Gordon, Lauren Jansson, Hendree Jones, Ingunn Olea Lund, Lana Popova, Ed Riley, Kathy Sulik (consultants on the reviews of the harm of substance use in pregnancy and breastfeeding); Margaret Harris (consultant in WHO guideline methodology, who prepared the guideline document and advised at the GDG meeting in Geneva); Keryn Murphy (who wrote the meeting report of the meeting in Washington DC); Nandi Siegfried (WHO consultant on systematic review, GRADE and WHO guideline methodology, and advisor at the GDG meeting in Washington DC, who conducted the reviews and prepared the GRADE tables on the effectiveness of interventions for substance use disorders).

*WHO interns:* Bonnie Cheuk, Helen Tam-Tham (interns who worked on the evidence of harms from substance use in pregnancy); Elise Gehring, Ifeoma Onyeka, Derrick Ssewanyana (interns who worked on the systematic reviews of effectiveness of interventions in pregnancy, the values and preferences survey and the preparation of the meeting in Geneva).

**The contribution of the Pan American Health Organization (PAHO)/WHO Regional Office for the Americas to the organization of the first meeting of the Guidelines Development Group in Washington DC (USA) is greatly acknowledged with special thanks to Maristela Monteiro, Jorge Rodriguez and Luiz Galvão.**

## **Special invitees to the initial meeting of the Guideline Development Group meeting in Washington DC (USA) who provided comment and technical information:**

Andreea A. Creanga, Louise Floyd (Centers for Disease Control and Prevention, USA); Anna Woods (Drug and Alcohol Services Council South Australia, Australia); Ed Riley (International Society for Biomedical Research on Alcoholism); Mary-Elizabeth Reeve, Christopher Howson (March of Dimes); Margaret M. Murray, Kathy Sulik (National Institute of Alcohol Abuse and Alcoholism (NIAAA), USA) Cheryl Anne Boyce, Steve Gust, Samia Dawud Noursi (National Institute on Drug Abuse (NIDA), USA); Kathy Mitchell (National Organization on Fetal Alcohol Syndrome (NOFAS), USA); Imani Walker (Rebecca Project for Human Rights, USA); Hedda van 't Land (Trimbos Institute, the Netherlands).

**Special invitees to the final meeting of the Guideline Development Group in Geneva, Switzerland, who provided technical information and contributed to external review:**

Andreea A. Creanga (Centers for Disease Control and Prevention, USA); Anna Woods (Drug and Alcohol Services Council, South Australia); Paul Peters (European Fetal Alcohol Spectrum Disorders Alliance); Andre Lalonde (International Federation of Gynecology and Obstetrics (FIGO), Partnership for Maternal, Newborn and Child Health (PMNCH); Mary Hepburn (Glasgow Special Needs in Pregnancy Service); Nester Moyo (International Confederation of Midwives); Yukiko Kusano (International Council of Nurses); Margaret M. Murray, Kathy Sulik (NIAAA, USA) Anne Boyce, Steve Gust, Samia Dawud Noursi (NIDA, USA); Kathy Mitchell (National Organization on Fetal Alcohol Syndrome (NOFAS), USA); Imani Walker (Rebecca Project For Human Rights, USA); Hedda van 't Land (Trimbos Institute, the Netherlands).

**Funding:** The project was funded by the Government of the United States of America (U.S. Department of State, Bureau for International Narcotics and Law Enforcement Affairs) through the United Nations Office on Drugs and Crime, and the Government of the Kingdom of Norway. The National Institute of Drug Abuse (NIDA), USA, and the National Institute of Alcohol Abuse and Alcoholism (NIAAA), USA, supported some evidence reviews and attendance of participants at the initial scoping meeting held in Washington DC, USA.

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?re>